Jardiance

Empagliflozin

Adjunct to diet & exercise to improve glycaemic control in adults w/ type 2 DM, as monotherapy when use of metformin is considered inappropriate due to intolerance; or as add-on combination therapy w/ other glucose-lowering medicinal products including insulin. Risk reduction of CV death in patients w/ type 2 DM & established CV disease. 10-mg FC tab: Treatment of symptomatic chronic heart failure.

Type 2 DM 10 mg once daily, can be increased to 25 mg once daily if additional glycaemic control is required. Heart failure 10 mg once daily. In heart failure patients w/ or w/o type 2 DM, 10 mg may be initiated or continued down to an eGFR 20 mL/min/1.73 m² or CrCl 20 mL/min.

May be taken with or without food.

Hypersensitivity. For type 2 DM: Patients w/ severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease & patients on dialysis.

Should not be used in patients w/ type 1 diabetes or for treatment of ketoacidosis. Discontinue immediately when ketoacidosis is suspected or diagnosed. Interrupt treatment in patients who are hospitalised for major surgical procedures or acute serious medical illnesses; may be restarted once patient's condition has stabilised. Discontinue in cases of recurrent UTI. Due to risk of modest BP decrease, exercise caution in patients w/ known CV disease, on diuretics, w/ history of hypotension or aged ≥75 yr. Monitoring of vol status & electrolytes are recommended. Regularly examine the feet & counsel patients on routine preventative footcare. Caution in patients at increased risk of genital infections. Positive result for glucose in urine test. For type 2 DM, should not be used in patients w/ severe renal impairment (eGFR <30 mL/min/1.73 m²), end-stage renal disease & patients on dialysis. For heart failure, not recommended when eGFR <20 mL/min/1.73 m². Avoid use during pregnancy & breast-feeding. Safety & effectiveness in childn <18 yr have not been established. Not recommended to initiate in patients ≥85 yr.

Hypoglycaemia (depends on type of background therapy); UTI, vag moniliasis, vulvovaginitis, balanitis & other genital infection; increased urination, dysuria; pruritus; vol depletion; thirst; decreased GFR, increased blood creatinine, increased haematocrit, increased serum lipids.

Increased risk of dehydration & hypotension w/ thiazide & loop diuretics. Risk of hypoglycemia w/ insulin or insulin secretagogues.

Antidiabetic Agents

A10BK03 - empagliflozin ; Belongs to the class of sodium-glucose co-transporter 2 (SGLT2) inhibitors. Used in the treatment of diabetes.

P₁S₁S₃